Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Its transforming growth factor beta (TGFβ) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | May 24, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 128 |
| CEO | Jay Backstrom |
Contact Details
Address: 301 Binney Street, 3rd Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 857 259 3860 |
| Website | scholarrock.com |
Stock Details
| Ticker Symbol | SRRK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001727196 |
| CUSIP Number | 80706P103 |
| ISIN Number | US80706P1030 |
| Employer ID | 82-3750435 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay Thomas Backstrom M.D., M.P.H. | President, Chief Executive Officer and Director |
| Mo Qatanani Ph.D. | Chief Scientific Officer |
| Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Erin Moore CPA | Interim Principal Financial and Accounting Officer |
| Rushmie Nofsinger | Vice President of Corporate Affairs and Investor Relations |
| Junlin Ho J.D. | General Counsel and Corporate Secretary |
| Caryn Parlavecchio | Chief Human Resources Officer |
| Edward H. Myles MBA | Senior Advisor |
| Lisa Amaya Price | Senior Vice President of Human Resources |
| Ryan Iarrobino | Senior Vice President of Clinical Development and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | ARS | Filing |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2025 | 144 | Filing |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |
| Mar 10, 2025 | 144 | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |